Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer.

Frontiers in endocrinology - 1 Jan 2026

Watanabe Mayu, Eguchi Jun, Takamoto Atsushi, Wada Jun

Abstract excerpt

Introduction: Tumor cells use immune checkpoint proteins such as programmed cell death 1 to escape immunological defenses. Immune checkpoint inhibitors (ICIs) that target these proteins have been used to treat several malignancies. ICI-induced diabetes is a rare but life-threatening adverse event. Our previous study evaluated pancreatic β-cell activity using the homeostasis model assessment of β-cell (HOMA-β)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles
Share to Diabetes Mellitus, Type 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DRB1 Chains

Share to Immune Checkpoint Inhibitors

Share to Neoplasms

Share to Prognosis

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42358679
DOI: 10.3389/fendo.2026.1789039
PMCID: PMC13290528

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer.PMID 42358679Read ↗

Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.Semantic proximity Read ↗

Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitorsSemantic proximity Read ↗

Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors.Semantic proximity Read ↗

Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implicationsSemantic proximity Read ↗

Clinical Characteristics and Human Leukocyte Antigens in patients with Immune Checkpoint Inhibitor-induced Type 1 Diabetes and Pituitary Dysfunction: A single center prospective studySemantic proximity Read ↗

Association between germ-line HLA and immune-related adverse eventsSemantic proximity Read ↗

Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in JapanSemantic proximity Read ↗

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity Read ↗

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse eventsSemantic proximity Read ↗

HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.Semantic proximity Read ↗

HLA investigation in ICI-induced T1D and isolated ACTH deficiency including meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.